Jun 2026 (Q2 FY26) — Aug 13, 2026
Biofrontera Q2 FY26 — Strong Revenue Growth and Path to Profitability
Read the full callBiofrontera (BFRI) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Biofrontera earnings: last reported Thu, 13 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 12.0 | +32.9% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -4.4 | +51.9 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -0.60 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$0.85 +2.41% · +$0.02
Performance −11.5% 1Y
1Y: $0.96 on 14 Oct 2025 → $0.85. High $1.61 (4 Sept 2026), low $0.57 (31 Dec 2025).
- Previous close
- $0.83
- 52-week range
- $0.57 – $1.61
- One year
- −13.27%
Overview
- Symbol
- BFRI
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Biofrontera earnings calls (BFRI)
Financials
What the filings say
Net profit, year on year: +89% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 9 | 13 | 9 | 9 | 7 | 17 | 10 | 12 |
| Expenses | 14 | 14 | 13 | 14 | 13 | 13 | 14 | 13 |
| Operating profit | -5 | -2 | -5 | -5 | -6 | 5 | -4 | -1 |
| Operating margin | −55.0% | −13.6% | −53.0% | −56.3% | −89.8% | 26.6% | −42.8% | −4.4% |
| Other income | -1 | 0 | 0 | -0 | -0 | 1 | -0 | -0 |
| Interest | — | — | 0 | — | — | — | — | — |
| Profit before tax | -6 | -1 | -4 | -5 | -7 | 6 | -5 | -1 |
| Tax rate | −0.1% | 0.1% | 0.0% | −0.4% | −0.1% | −0.0% | — | −4.0% |
| Net profit | -6 | -1 | -4 | -5 | -7 | 6 | -5 | -1 |
| EPS ($ per share) | -0.98 | — | -0.47 | -0.57 | -0.62 | — | -0.41 | -0.05 |
| Line item | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -41 | -79 | -80 | -100 | -117 | -128 |
| Total liabilities | 18 | 42 | 27 | 23 | 18 | 18 |
| Fixed assets | 0 | 0 | 0 | 0 | 0 | 2 |
| Total assets | 24 | 53 | 51 | 28 | 22 | 29 |
| Line item | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Cash from operations | -12 | -27 | -16 | -25 | -10 | -13 |
| Cash from investing | — | -0 | -5 | 1 | -0 | 3 |
| Cash from financing | 13 | 43 | 14 | 8 | 15 | 11 |
| Net cash flow | 1 | 16 | -7 | -16 | 5 | 0 |
| Capital expenditure | — | — | -0 | -0 | -0 | -0 |
| Free cash flow | — | — | -16 | -25 | -10 | -13 |
Insider filings
4 filings between Mar 5, 2026 and Jul 28, 2026.
Open market
decisions to buy or sellNobody bought or sold BFRI on the open market in this window. The filings below are 4 option exercises.
Compensation
not trading decisions- 4
- Option exercise — converted options into shares
Latest filings (6)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jul 28, 2026 | Leffler Eugene Frederick Chief Financial Officer | Option exercise | 31,250 | — |
| Jul 28, 2026 | Luebbert Hermann CEO & Chairman | Option exercise | 62,500 | — |
| Mar 5, 2026 | Leffler Eugene Frederick Chief Financial Officer | Option exercise | 87,500 | — |
| Mar 5, 2026 | Luebbert Hermann CEO & Chairman | Option exercise | 137,500 | — |
| Sep 10, 2025 | Leffler Eugene Frederick Chief Financial Officer | Option exercise | 87,500 | — |
| Sep 10, 2025 | Luebbert Hermann CEO & Chairman | Option exercise | 137,500 | — |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Biofrontera Inc.
Free account. Everything above stays public.
Write why you follow Biofrontera Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading